Lyndon Brown

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP₂ Receptor Antagonist for Treatment of Asthma

David A. Sandham, Lucy Barker, Lyndon Brown et al. · ACS Medicinal Chemistry Letters · 2017 · 35 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate

Neil J. Press, Roger Taylor, Joseph D. Fullerton et al. · Journal of Medicinal Chemistry · 2012 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential

Neil J. Press, Neil J. Press, Roger Taylor et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 31 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +5

Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases

David A. Sandham, Nicola Arnold, Heinrich Aschauer et al. · Bioorganic & Medicinal Chemistry · 2013 · 22 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +9

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Neil J. Press, Roger Taylor, Joseph D. Fullerton et al. · Journal of Medicinal Chemistry · 2015 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16